Why This Landed on My Radar
If you’ve been following the shift from IV to subcutaneous formulations of blockbuster cancer immunotherapies, this one’s going to sting. CMS just proposed closing what they’re calling a “loophole” that’s been protecting drugs like subcutaneous Keytruda and Opdivo from Medicare price negotiations. For those of us who’ve invested in infusion capabilities or are managing oncology patients, this isn’t just policy wonk stuff - it’s a direct hit to how we think about specialty drug revenue and patient access going forward.
Here’s What’s Going On
CMS has proposed a rule change for 2029 that would make subcutaneous formulations of cancer immunotherapies eligible for Medicare drug price negotiations, even when they’re relatively new to market. Here’s the backdrop: when drugmakers develop a subcutaneous version of an existing IV drug, it technically becomes a “new” product with its own approval date. Under current rules, drugs need to be on the market for a certain number of years before they’re eligible for Medicare’s negotiation program.
Pharmaceutical companies have been transitioning blockbuster cancer drugs like Merck’s Keytruda and Bristol Myers Squibb’s Opdivo from IV to subcutaneous formulations - a move that’s genuinely better for patients (faster administration, potential for home use) but also conveniently resets the clock on price negotiation eligibility. CMS is now saying: not so fast. The proposed rule would treat these subcutaneous versions as extensions of the original IV drug for pricing purposes, making them eligible for negotiation based on when the original formulation hit the market, not when the new delivery method launched.
The administration is framing this as closing a “loophole,” while drugmakers argue it could discourage innovation in drug delivery methods. Either way, it’s happening, and the comment period is already underway.
What This Means for Your Practice
Let’s be honest about what this means for those of us in primary care, especially if you’re managing or co-managing cancer patients. On the surface, this seems like an oncology-specific issue, but it ripples out to us in several ways.
First, if you’ve been considering adding infusion services or already have them, the economics just shifted. Lower negotiated prices on these heavy-hitter drugs means tighter margins on administration. In Texas, where we’re already fighting with BCBS and United on reimbursement for everything, this adds another layer of complexity to the math on whether specialty services pencil out for independent practices.
Second, and this is where it gets interesting for our patient populations: Texas has the highest uninsured rate in the country, and many of our Medicaid-eligible patients can’t access coverage because we didn’t expand. When Medicare negotiates lower prices, it often creates a trickle-down effect on commercial payer negotiations and patient assistance programs. That could mean better access for our dual-eligible and struggling patients - but it also means we need to stay on top of which formulations are covered and at what tier.
Third, this is a preview of where drug pricing policy is headed. CMS isn’t going to stop with subcutaneous cancer drugs. They’re getting smarter about pharmaceutical industry strategies, and we need to get smarter about how these policy shifts affect our formularies, our prior auth battles, and our ability to keep patients on effective therapies without bankrupting them.
For those of us in rural Texas, there’s another wrinkle: subcutaneous formulations were supposed to reduce the need for patients to travel to infusion centers. If price negotiations make these formulations less attractive for manufacturers to develop or for systems to stock, we’re back to sending patients on two-hour drives for IV infusions. That’s not theoretical - it’s already hard enough to keep specialty drugs available in critical access areas.
Key Takeaways
- CMS’s 2029 rule targets subcutaneous versions of IV cancer drugs for price negotiations, treating them as extensions of the original drug rather than new products
- If you offer infusion services, model out how tighter drug margins affect your bottom line - the economics of specialty services just got more complicated
- Stay ahead of formulary changes - negotiated prices will shift what’s on preferred lists and what requires prior auth
- Rural practices should pay attention - this could affect whether subcutaneous options remain widely available for patients who can’t easily access infusion centers
- This is a template for future CMS policy - expect more sophisticated approaches to closing what regulators see as pricing loopholes
What Smart Practices Are Doing
The savvy practices I’m talking to aren’t waiting until 2029 to react. They’re already stress-testing their specialty drug economics with lower reimbursement assumptions and building better systems to track formulary changes in real-time. More importantly, they’re investing in tools that can flag when a patient’s prescribed drug hits a coverage or pricing change - because finding out at the pharmacy counter is too late.
Source
Medicare drug price rule may target under-the-skin cancer immunotherapies - Healthcare Dive
Primary Care Perspective delivers curated intelligence from trusted healthcare sources.
© 2026 Primary Care Perspective | Texas Edition